<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347319</url>
  </required_header>
  <id_info>
    <org_study_id>P2010-PN004</org_study_id>
    <nct_id>NCT02347319</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver Disease</brief_title>
  <official_title>A Double-Blind, Randomized, Multicenter Trial Examining the Efficacy of Biphenyl Dimethyl Dicarboxylate Combined With Garlic Oil in Patients With Transaminase Elevated Chronic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaKing</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaKing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose

      - To evaluate the efficacy of Biphenyl dimethyl dicarboxylate(DDB)/Garlic Oil in patients
      with elevated transaminase chronic liver disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biphenyl dimethyl dicarboxylate (DDB) combined with garlic oil (pennel) has been used to
      treat chronic liver disease. A randomized, double-blind, active- and placebo-controlled
      clinical trial was conducted to investigate the efficacy, safety and quality of life in
      chronic liver disease patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Normalized rate in serum ALT</measure>
    <time_frame>12 weeks</time_frame>
    <description>The rate of alanine aminotransferase (ALT) normalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Î³-GTP</measure>
    <time_frame>8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST/ALT ratio</measure>
    <time_frame>8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALP</measure>
    <time_frame>8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin</measure>
    <time_frame>8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin</measure>
    <time_frame>8, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The assessment of health-related quality of life</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">262</enrollment>
  <condition>Chronic Liver Disease</condition>
  <arm_group>
    <arm_group_label>Pennel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will treated with DDB 25mg/Garlic oil 50mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Legalon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will treated with Silymarin 140mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will treated with Placebo for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pennel</intervention_name>
    <description>Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid</description>
    <arm_group_label>Pennel</arm_group_label>
    <other_name>DDB/Garlic oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Legalon</intervention_name>
    <description>Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid</description>
    <arm_group_label>Legalon</arm_group_label>
    <other_name>Silymarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Lactose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 20years of age

          -  Patients with more 60 ALT in screening period.

          -  To evaluate ALT and AST at least three months.

          -  Serum Transaminase abnormal(before 6months), chronic liver disease or fatty liver,
             liver disease medical treatment at more than 30days

          -  Women of childbearing age get her consent for contraception, pregnancy urine test
             result negative.

        Exclusion Criteria:

          -  ALT&gt;10UNL on screening period.

          -  Current treatment on another clinical trial

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The catholic university of korea, Bucheon ST. Mary's Hosipital</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
    <mesh_term>Allyl sulfide</mesh_term>
    <mesh_term>7,7'-dimethoxy-(4,4'-bi-1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

